Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and pharmacokinetics of capecitabine (2000
mg/m2/day by mouth [po], day 1 pm-day 15 am every 3 weeks [q3w]), oxaliplatin (130 mg/m2
intravenously [iv], day 1 q3w) and bevacizumab (7.5 mg/kg iv, day 1 q3w) in patients with
advanced and/or metastatic colorectal cancer.